Clinical trials: Urinary Infections
Respiratory Tract Infections, Urinary Tract Infections
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
This study aims to evaluate the diagnostic and prognostic performance of a novel mRNA diagnostic/prognostic classifier (interprets the expression of 29 host response mRNA biomarkers) from whole blood in adult patients presenting…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- NCT05639504
- Testing
- IMX-BVN-4 and IMX-SEV-4
- Sponsor
- Inflammatix
Acute Lower Urinary Tract Infection
A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control
prulifloxacin is not inferior to levofloxacin hydrochloride in treating acute uncomplicated lower urinary tract infection in chinese
- Trial name
- NCT02439632
- Testing
- prulifloxacin, Levofloxacin
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Lee's Pharmaceutical Limited
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Urinary Catheters, Urinary Tract Infection
Clinical Study on Disposable Sterile Urinary Catheter
This study is a multicenter, randomized controlled study, with the urinary tract infection rate at the time of catheter insertion for 1 week as the primary end point.
- Trial name
- NCT05651217
- Testing
- disposable urinary catheter, super smooth antibacterial urinary catheter
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response…
- Trial name
- NCT05138822
- Testing
- GSK3882347, Nitrofurantoin
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Urinary Tract Infections, Pyelonephritis Acute
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous sulopenem and oral sulopenem etzadroxil/probenecid in adolescent patients.
- Conditions
- Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
- Trial name
- NCT04700787
- Testing
- Sulopenem
- Where
- United States
- Sponsor
- Iterum Therapeutics, International Limited
Urinary Tract Infections, Complicated Urinary Tract Infection
Evaluating UTI Outcomes in at Risk Populations
This is a multicenter, observational comparative cohort, study to evaluate the UTI related adverse event rates between Guidance® UTI clinical pathway versus the current traditional clinical pathways for urine testing.
- Trial name
- At Risk (NCT05385536)
- Where
- United States
- Volunteers
- 7,921 people
- Sponsor
- Pathnostics
UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Clinical Impact Analysis of PA-100 AST in a Spanish GP Setting
Assessment of workflow implications of the PA-100 AST System. Using well-defined data collection protocols, the study comprises the following: Collection of clean-catch midstream urine samples Measurement of specimens on the…
- Conditions
- UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection, AMR, Cystitis Acute
- Trial name
- NCT07189429
- Testing
- PA-100 AST
- Where
- Spain
- Volunteers
- 199 people
- Sponsor
- Sysmex Europe GmbH
Urinary Tract Infections
Effect of Probiotics on Recurrent Urinary Tract Infections
Randomized clinical trial to evaluate the effect of a probiotic mixture of Lactobacillus plantarum on recurrent urinary tract infections in women.
- Trial name
- CYSCARE (NCT06192966)
- Testing
- Food supplement
- Where
- 4 sites in Spain
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
This is a Phase 2 randomized open label multicentre three arm comparative study evaluating the efficacy safety tolerability and pharmacokinetics of intravenous ertapenem zidebactam ERT ZID compared with ceftazidime avibactam CAZ…
- Trial name
- NCT07840105
- Testing
- Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam
- Where
- 19 sites in India
- Volunteers
- 279 people
- Sponsor
- Wockhardt
BK Virus Infection, Hemorrhagic Cystitis
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).
- Trial name
- NCT04390113
- Testing
- Posoleucel (ALVR105)
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 97 people
- Sponsor
- AlloVir
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Asymptomatic Bacteriuria
Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients
The purpose of this clinical trial is to study the effects of NVC-422 instilled into the bladder in reducing bacteria in the urine.
- Trial name
- NCT00781339
- Testing
- sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Recurrent Urinary Tract Infection
Nutritional Supplementation for Recurrent Urinary Tract Infections in Women
The study will test the ability of specially formulated nutritional supplement capsules to extend the time between recurrent urinary tract infections in women.
- Trial name
- NCT03597152
- Testing
- WelTract
- Volunteers
- 250 people
- Sponsor
- AmPurity Nutraceuticals, LLC
Urinary Tract Infection(UTI)
A Clinical Trial to Investigate the Safety and Efficacy of D-Mannose on Symptoms of Urinary Tract Infection in Women
The objective of this acute study was to investigate the safety and efficacy of UClear for the resolution of urinary tract infection (UTI) symptoms in women. The main questions it aims to answer is: 1.
- Trial name
- NCT06719115
- Testing
- UClear
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- KEB Nutraceuticals USA, Inc.
Urinary Tract Infections, Pyelonephritis
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis.
- Trial name
- NCT06128213
- Testing
- NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))
- Volunteers
- 13 people
- Sponsor
- NeuroRx, Inc.
Urinary Tract Infections
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
To assess if a bacteriophobic coating prevents biofilm and host protein accumulation on urinary catheters and inflammatory protein release in urine following catheterization
- Trial name
- PRO033CSP (NCT05719753)
- Testing
- Camstent Coated Catheter, Standard Care
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Camstent Ltd.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG